Literature DB >> 21273305

KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.

Youl-Nam Lee1, Stephanie Brandal, Pierre Noel, Erik Wentzel, Joshua T Mendell, Michael A McDevitt, Reuben Kapur, Melody Carter, Dean D Metcalfe, Clifford M Takemoto.   

Abstract

Activating mutations in codon D816 of the tyrosine kinase receptor, KIT, are found in the majority of patients with systemic mastocytosis. We found that the transcription factor, microphthalmia-associated transcription factor (MITF), is highly expressed in bone marrow biopsies from 9 of 10 patients with systemic mastocytosis and activating c-KIT mutations. In primary and transformed mast cells, we show that KIT signaling markedly up-regulates MITF protein. We demonstrate that MITF is required for the proliferative phenotype by inhibiting colony-forming units with sh-RNA knockdown of MITF. Furthermore, constitutively active KIT does not restore growth of primary MITF-deficient mast cells. MITF mRNA levels do not change significantly with KIT signaling, suggesting posttranscriptional regulation. An array screen from mast cells identified candidate miRNAs regulated by KIT signaling. We found that miR-539 and miR-381 are down-regulated by KIT signaling and they repressed MITF expression through conserved miRNA binding sites in the MITF 3'-untranslated region. Forced expression of these miRNAs suppressed MITF protein and inhibited colony-forming capacity of mastocytosis cell lines. This work demonstrates a novel regulatory pathway between 2 critical mast cell factors, KIT and MITF, mediated by miRNAs; dysregulation of this pathway may contribute to abnormal mast cell proliferation and malignant mast cell diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21273305      PMCID: PMC3072881          DOI: 10.1182/blood-2010-07-293548

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.

Authors:  C Akin; A S Kirshenbaum; T Semere; A S Worobec; L M Scott; D D Metcalfe
Journal:  Exp Hematol       Date:  2000-02       Impact factor: 3.084

2.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.

Authors:  M Wu; T J Hemesath; C M Takemoto; M A Horstmann; A G Wells; E R Price; D Z Fisher; D E Fisher
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

Review 3.  Steel locus defines new multipotent growth factor.

Authors:  O N Witte
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

4.  Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.

Authors:  Sebastian Bauer; Joshua A Parry; Thomas Mühlenberg; Matthew F Brown; Danushka Seneviratne; Payel Chatterjee; Anna Chin; Brian P Rubin; Shih-Fan Kuan; Jonathan A Fletcher; Stefan Duensing; Anette Duensing
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

Review 5.  c-Kit and c-kit mutations in mastocytosis and other hematological diseases.

Authors:  M Boissan; F Feger; J J Guillosson; M Arock
Journal:  J Leukoc Biol       Date:  2000-02       Impact factor: 4.962

6.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference.

Authors:  Douglas A Rubinson; Christopher P Dillon; Adam V Kwiatkowski; Claudia Sievers; Lili Yang; Johnny Kopinja; Dina L Rooney; Mingdi Zhang; Melanie M Ihrig; Michael T McManus; Frank B Gertler; Martin L Scott; Luk Van Parijs
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

7.  Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver.

Authors:  Petranel T Ferrao; Thomas J Gonda; Leonie K Ashman
Journal:  Leuk Res       Date:  2003-06       Impact factor: 3.156

Review 8.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Authors:  Cem Akin; Gerard Fumo; Akif S Yavuz; Peter E Lipsky; Len Neckers; Dean D Metcalfe
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

Review 10.  Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.

Authors:  B M Jensen; C Akin; A M Gilfillan
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

View more
  29 in total

1.  MicroRNA-381 increases radiosensitivity in esophageal squamous cell carcinoma.

Authors:  Suna Zhou; Wenguang Ye; Juan Ren; Qiuju Shao; Yuhong Qi; Jun Liang; Mingxin Zhang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  miR-539 as a key negative regulator of the MEK pathway in myocardial infarction.

Authors:  J Hui; W Huishan; L Tao; Y Zhonglu; Z Renteng; H Hongguang
Journal:  Herz       Date:  2016-12-15       Impact factor: 1.443

3.  The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.

Authors:  Erola Ainsua-Enrich; Eva Serrano-Candelas; Damiana Álvarez-Errico; César Picado; Joan Sayós; Juan Rivera; Margarita Martín
Journal:  J Immunol       Date:  2015-03-25       Impact factor: 5.422

4.  MicroRNA-539 is up-regulated in failing heart, and suppresses O-GlcNAcase expression.

Authors:  Senthilkumar Muthusamy; Angelica M DeMartino; Lewis J Watson; Kenneth R Brittian; Ayesha Zafir; Sujith Dassanayaka; Kyung U Hong; Steven P Jones
Journal:  J Biol Chem       Date:  2014-09-02       Impact factor: 5.157

Review 5.  The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis.

Authors:  Leonidas Benetatos; Eleftheria Hatzimichael; Eric Londin; George Vartholomatos; Phillipe Loher; Isidore Rigoutsos; Evangelos Briasoulis
Journal:  Cell Mol Life Sci       Date:  2012-07-24       Impact factor: 9.261

6.  Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

Authors:  Lakshmi Reddy Palam; Raghuveer Singh Mali; Baskar Ramdas; Sridhar Nonavinkere Srivatsan; Valeria Visconte; Ramon V Tiu; Bart Vanhaesebroeck; Axel Roers; Alexander Gerbaulet; Mingjiang Xu; Sarath Chandra Janga; Clifford M Takemoto; Sophie Paczesny; Reuben Kapur
Journal:  JCI Insight       Date:  2018-02-22

7.  Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts.

Authors:  Hao Hu; Yi Zhang; Xian-Hua Cai; Ji-Feng Huang; Lin Cai
Journal:  Oncol Lett       Date:  2012-08-16       Impact factor: 2.967

8.  Balanced interactions between Lyn, the p85alpha regulatory subunit of class I(A) phosphatidylinositol-3-kinase, and SHIP are essential for mast cell growth and maturation.

Authors:  Peilin Ma; Sasidhar Vemula; Veerendra Munugalavadla; Jinbiao Chen; Emily Sims; Jovencio Borneo; Takako Kondo; Baskar Ramdas; Raghuveer Singh Mali; Shuo Li; Eri Hashino; Clifford Takemoto; Reuben Kapur
Journal:  Mol Cell Biol       Date:  2011-07-26       Impact factor: 4.272

9.  Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis.

Authors:  Paul J Bryce; Rustom Falahati; Laurie L Kenney; John Leung; Christopher Bebbington; Nenad Tomasevic; Rebecca A Krier; Chia-Lin Hsu; Leonard D Shultz; Dale L Greiner; Michael A Brehm
Journal:  J Allergy Clin Immunol       Date:  2016-04-06       Impact factor: 10.793

Review 10.  Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.

Authors:  Glenn Cruse; Dean D Metcalfe; Ana Olivera
Journal:  Immunol Allergy Clin North Am       Date:  2014-03-12       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.